ライフサイエンスコーパス: glucose clamp

1 nia and/or systemic hypoglycemia (2.8 mmol/l glucose clamp).

2 els were similar among all groups during the glucose clamp.

3 cemic (5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp.

4 th a stepped hyperinsulinaemic hypoglycaemic glucose clamp.

5 liver and the peripheral tissues during the glucose clamp.

6 ng recovery (5-6 mmol/L) by hyperinsulinemic glucose clamp.

7 mmol/L) hypoglycemic (2.80 +/- 0.12 mmol/L) glucose clamp.

8 three periods of hypoglycemia by an insulin-glucose clamp.

9 Insulin sensitivity was assessed by glucose clamps.

10 ovement in glucose disposal rates during the glucose clamps.

11 ormed on the day before the second and third glucose clamps.

12 ximately 3.6 mmol/l, approximately 65 mg/dl) glucose clamps.

13 red hourly during a basal insulin euglycemic glucose clamp (0.2mU x min(-1) x kg(-1)).

14 during a 100-min hyperinsulinemic-euglycemic glucose clamp (40 mU x m(-2) x min(-1)) before and after

15 During the glucose clamps, adiponectin levels were suppressed below

16 During glucose clamp adjustment of blood glucose levels, it was

17 Results from simulated glucose clamps also agree quantitatively with recent GRI

18 Here, we combined two techniques - glucose clamps and in vivo microdialysis - as a means to

19 in sensitivity (hyperinsulinemic-isoglycemic glucose clamp) and insulin-stimulated changes in brachia

20 intravenous (ivGTT) glucose tolerance tests, glucose clamps, and body composition assessed between 15

21 er changes in HK-II expression seen during a glucose clamp are likely to be physiologically relevant,

22 tudies were conducted with maternal arterial glucose clamped at 5 micromol ml(-1) and fetal glucose a

23 emission tomography during hyperinsulinemic glucose clamps at nominal plasma glucose concentrations

24 . m(-2). min(-1) hyperinsulinemic-euglycemic glucose clamp before and after 3 months' treatment with

25 was assessed by hyperinsulinemic-euglycemic glucose clamp before and after intranasal application of

26 Under glucose clamp conditions (study 2), the change in plasma

27 PET studies performed under glucose clamp conditions demonstrated that the uptake of

28 Under glucose clamp conditions, rats were imaged at the baseli

29 n contrast, insulin action (hyperinsulinemic glucose clamp) did not correlate with the age at onset o

30 l range (2.0-2.5-microm wavelength) during a glucose clamp experiment in order to identify the presen

31 In glucose clamp experiments conducted in healthy dogs, as

32 ype 1 diabetes underwent 4 separate stepwise glucose clamps (five 30-min steps from fasting level to

33 erglycemic condition was produced in rats by glucose clamp for 3 hrs.

34 a hyperinsulinemic-hypoglycemic (2.5 mmol/l) glucose clamp for 90 min.

35 Suppression of EGP during the glucose clamps, however, was impaired.

36 lucose uptake by euglycemic-hyperinsulinemic glucose clamp in 15 normal-weight and 15 obese participa

37 mpared with the tolbutamide protocol and the glucose clamp in 35 nondiabetic subjects (age 38 +/- 2 y

38 od flow, necessitating the two approaches to glucose clamping in the cGMP groups.

39 is, we performed euglycemic-hyperinsulinemic glucose clamps in conscious dogs (n = 8) in which FFA we

40 and plasma FFA concentrations throughout the glucose clamps in control (r = 0.996) and GDM (r = 0.995

41 lin therapy displayed a significantly higher glucose clamp infusion rate posttreatment (9.1 +/- 1.3 i

42 onostatic potency of GLP-1 during a stepwise glucose clamp is preserved in patients with type 2 diabe

43 e test (OGTT) and an isoglycemic intravenous glucose clamp (iso-IVGC) in: 1) 16 severely obese patien

44 blood glucose levels were manipulated using glucose clamp methodologies with continuous basal insuli

45 nsitivity during late pregnancy, but neither glucose clamp nor minimal model measures of insulin sens

46 followed by a hyperinsulinemic/hypoglycemic glucose clamp on day 4.

47 those based on an intravenous test (e.g., a glucose clamp or an intravenous glucose tolerance test).

48 oration of insulin sensitivity quantified by glucose clamp or minimal model.

49 few data using direct measures of IR such as glucose clamps or frequently sampled intravenous glucose

50 t and exercise using a pancreatic clamp with glucose clamped (PC/GC; n = 5), a pancreatic clamp with

51 Glucose clamp procedures were used to determine whether

52 mmol/l) or hypoglycemic (2.9 +/- 0.1 mmol/l) glucose clamps (prolonged hypoglycemia) were carried out

53 old (by intralipid infusion during 11 mmol/l glucose clamp) resulted in a robust, approximate twofold

54 was assessed by hyperinsulinemic-isoglycemic glucose clamp (SI(Clamp)) and endothelial function evalu

55 rnoon 2-h hyperinsulinemic (528+/-30 pmol/l) glucose clamp studies of 5.3+/-0.1 mmol/l (euglycemic co

56 The glucose clamp studies were performed at submaximal (4 mU

57 ests (ITTs), and hyperinsulinemic euglycemic glucose clamp studies, we demonstrated that mice lacking

58 essed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheterized awake ma

59 g field data (Raman spectra) acquired from a glucose clamping study on an animal model subject, we pe

60 in intracerebral glucose levels during a 2-h glucose clamp (target glucose concentration 220 mg/dL).

61 Insulin sensitivity was measured using the glucose clamp technique (40 mU.m-2.min-1), in conjunctio

62 The hyperinsulinemic-euglycemic glucose clamp technique and intravenous-glucose-toleranc

63 dy and individual skeletal muscles using the glucose clamp technique combined with D-[3-3H]glucose in

64 ased models and their validation against the glucose clamp technique.

65 10%) by using a modification of the insulin/glucose clamp technique.

66 sensitivity had been characterized using the glucose clamp. technique.

67 ucose levels of 5 and 2.6 mmol/l, applied by glucose clamp techniques, in random order.

68 The modified glucose clamp was performed in the presence of postprand

69 A hyperinsulinemic glucose clamp was used to lower blood glucose to 2.5 mmo

70 A hyperinsulinaemic glucose clamp was used to maintain plasma glucose at 5 m

71 Euglycemic glucose clamps were performed in anesthetized dogs (n =

72 mmol/L) and hypoglycemic (3 mmol/L) [1-(13)C]glucose clamps were performed in eight healthy subjects

73 hyperinsulinemic euglycemic and hypoglycemic glucose clamps were performed on separate days, using [1

74 and type 2 diabetic volunteers (n = 8 each); glucose clamps were used to assess insulin sensitivity.

75 To test this question, phloridzin-glucose clamps were used to match blood glucose and panc

76 mg/kg estimated metabolic body size/min, by glucose clamp) were measured.